Skip to content
ATLAS PREP HQ
Longevity

Epitalon

Ala-Glu-Asp-Gly (AEDG), also called Epithalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Limited Human Evidence

Route

Subcutaneous in the community protocol

Common format

10 mg vial

Research focus

telomerase/telomeres

Evidence level

Limited Human Evidence

Typical cycle

10–20 days

Longevity research motifLongevity

Epitalon in 30 seconds

Atlas Fast Read

What it is

Ala-Glu-Asp-Gly (AEDG), also called Epithalon

Why people care

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

Epitalon has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is Epitalon?

Epitalon is ala-Glu-Asp-Gly (AEDG), also called Epithalon. Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Developed by Vladimir Khavinson and colleagues from pineal-peptide research in the late Soviet/Russian gerontology program. It became known for telomerase and circadian claims, but most human work is small, older, and geographically concentrated.

Mechanism

How it works

In vitro studies report telomerase activation and telomere effects, while animal and small human studies suggest effects on pineal/circadian signaling and melatonin. The molecular pathway behind claimed systemic longevity effects remains uncertain.

Research areas

telomerase/telomerescircadian biologymelatoninaging research

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Small and older human studies from the Khavinson research program have reported effects on circadian markers, mortality, or age-related outcomes, but the studies are limited by size, geography, methodology, and independent replication. Human evidence is therefore suggestive rather than strong.

Preclinical evidence

Cell studies report telomerase activation and telomere-related effects; animal work reports circadian, antioxidant, reproductive, and lifespan-related signals. These results remain difficult to translate into a clinically validated anti-aging effect.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 5 mg/day for 20 consecutive days; an alternative listed is 10 mg/day for 10 days. These are not established clinical standards.

Frequency

Once daily during the short cycle.

Timing

Often evening/bedtime in the community protocol because of the circadian research hypothesis.

Route

Subcutaneous in the community protocol; other research has used different routes.

Cycle length

10–20 days

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C, protect from light and avoid freeze-thaw.

Monitoring

No validated longevity monitoring standard. CBC/CMP are general safety labs; sleep/circadian measures can track the stated research target. Telomere testing is not a proven treatment-monitoring tool.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human safety data are insufficient. Potential adverse effects include injection-site reactions, headache, fatigue, dizziness, nausea and unknown long-term effects on gene regulation, growth, metabolism or immune function.

Contraindications

No validated human contraindication profile exists. Avoid use outside research oversight in pregnancy/breastfeeding, active malignancy, significant organ disease or known hypersensitivity.

Interactions

Formal drug-interaction studies are absent or very limited. Interactions with anticancer, endocrine, metabolic and immunomodulatory therapies are unknown.

Stacks

Common stacks

Epitalon + mitochondrial-focused compounds

Sometimes grouped with NAD+, MOTS-c or SS-31 in longevity communities.

No controlled evidence that such stacks extend human lifespan or healthspan.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Epitalon has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.

More in Longevity

Longevity

Cortagen

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Read guide

Longevity

FOXO4-DRI

Experimental senolytic peptide research investigating selective removal of senescent cells.

Read guide

Longevity

Glutathione

Antioxidant research focused on redox balance, oxidative stress, and cellular detoxification pathways.

Read guide